BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36204592)

  • 1. Investigation on the self-assembly of the NFL-TBS.40-63 peptide and its interaction with gold nanoparticles as a delivery agent for glioblastoma.
    Alnemeh-Al Ali H; Griveau A; Artzner F; Dupont A; Lautram N; Jourdain MA; Eyer J
    Int J Pharm X; 2022 Dec; 4():100128. PubMed ID: 36204592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological activity of gold nanoparticles combined with the NFL-TBS.40-63 peptide, or with other cell penetrating peptides, on rat glioblastoma cells.
    Griveau A; Arib C; Spadavecchia J; Eyer J
    Int J Pharm X; 2022 Dec; 4():100129. PubMed ID: 36164551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and quantification of the interaction between the NFL-TBS.40-63 peptide and lipid nanocapsules.
    Griveau A; Alnemeh-Al Ali H; Jourdain MA; Dupont A; Eyer J
    Int J Pharm X; 2022 Dec; 4():100127. PubMed ID: 36177093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the functionalization of liposomes with NFL-TBS. 40-63 peptide as a promising drug delivery system.
    Jourdain MA; Dupont A; Lautram N; Eyer J
    Int J Pharm; 2024 Mar; 652():123805. PubMed ID: 38237710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NFL-TBS.40-63 anti-glioblastoma peptide enters selectively in glioma cells by endocytosis.
    Lépinoux-Chambaud C; Eyer J
    Int J Pharm; 2013 Oct; 454(2):738-47. PubMed ID: 23603097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NFL-TBS.40-63 Peptide Gold Complex Nanovector: A Novel Therapeutic Approach to Increase Anticancer Activity by Breakdown of Microtubules in Pancreatic Adenocarcinoma (PDAC).
    Liu Q; Liu H; Griveau A; Li X; Eyer J; Arib C; Spadavecchia J
    ACS Pharmacol Transl Sci; 2022 Dec; 5(12):1267-1278. PubMed ID: 36524008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell penetrating peptide (CPP) gold(iii) - complex - bioconjugates: from chemical design to interaction with cancer cells for nanomedicine applications.
    Arib C; Griveau A; Eyer J; Spadavecchia J
    Nanoscale Adv; 2022 Jul; 4(14):3010-3022. PubMed ID: 36133522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Neurofilament-Derived Peptide NFL-TBS.40-63 Targets Neural Stem Cells and Affects Their Properties.
    Lépinoux-Chambaud C; Barreau K; Eyer J
    Stem Cells Transl Med; 2016 Jul; 5(7):901-13. PubMed ID: 27177578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofilament-tubulin binding site peptide NFL-TBS.40-63 increases the differentiation of oligodendrocytes in vitro and partially prevents them from lysophosphatidyl choline toxiciy.
    Fressinaud C; Eyer J
    J Neurosci Res; 2014 Feb; 92(2):243-53. PubMed ID: 24327347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the NFL-TBS.40-63 peptide on canine glioblastoma cells.
    Audrey G; Claire LC; Joel E
    Int J Pharm; 2021 Aug; 605():120811. PubMed ID: 34144141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of liposomes functionalized with the NFL-TBS.40-63 peptide as a targeting agent to cross the in vitro blood-brain barrier and target glioblastoma cells.
    Mellinger A; Lubitz LJ; Gazaille C; Leneweit G; Bastiat G; Lépinoux-Chambaud C; Eyer J
    Int J Pharm; 2023 Nov; 646():123421. PubMed ID: 37722495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofilaments and NFL-TBS.40-63 peptide penetrate oligodendrocytes through clathrin-dependent endocytosis to promote their growth and survival in vitro.
    Fressinaud C; Eyer J
    Neuroscience; 2015 Jul; 298():42-51. PubMed ID: 25862585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of functionalizing lipid nanocapsules with NFL-TBS.40-63 peptide on their uptake by glioblastoma cells.
    Balzeau J; Pinier M; Berges R; Saulnier P; Benoit JP; Eyer J
    Biomaterials; 2013 Apr; 34(13):3381-9. PubMed ID: 23391494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell penetrating peptide decorated magnetic porous silicon nanorods for glioblastoma therapy and imaging.
    Chaix A; Griveau A; Defforge T; Grimal V; Le Borgne B; Gautier G; Eyer J
    RSC Adv; 2022 Apr; 12(19):11708-11714. PubMed ID: 35432942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid Nanoparticles Vectorized with NFL-TBS.40-63 Peptide Target Oligodendrocytes and Promote Neurotrophin-3 Effects After Demyelination In Vitro.
    Fressinaud C; Thomas O; Umerska AM; Saulnier P
    Neurochem Res; 2020 Nov; 45(11):2732-2748. PubMed ID: 32910302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NFL-TBS.40-63 peptide targets and kills glioblastoma stem cells derived from human patients and also targets nanocapsules into these cells.
    Lépinoux-Chambaud C; Eyer J
    Int J Pharm; 2019 Jul; 566():218-228. PubMed ID: 31132447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the Structural Variability and Binding Modes of the Glioma Targeting NFL-TBS.40-63 Peptide on Tubulin.
    Laurin Y; Savarin P; Robert CH; Takahashi M; Eyer J; Prevost C; Sacquin-Mora S
    Biochemistry; 2015 Jun; 54(23):3660-9. PubMed ID: 26016807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-function analysis of the glioma targeting NFL-TBS.40-63 peptide corresponding to the tubulin-binding site on the light neurofilament subunit.
    Berges R; Balzeau J; Takahashi M; Prevost C; Eyer J
    PLoS One; 2012; 7(11):e49436. PubMed ID: 23152907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-assembled chiral helical nanofibers by amphiphilic dipeptide derived from d- or l-threonine and application as a template for the synthesis of Au and Ag nanoparticles.
    Zhang H; Xin X; Sun J; Zhao L; Shen J; Song Z; Yuan S
    J Colloid Interface Sci; 2016 Dec; 484():97-106. PubMed ID: 27592190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Biological Material Adsorption to the Surface of Nanoparticles without a Prior Separation Step: a Case Study of Glioblastoma-Targeting Peptide and Lipid Nanocapsules.
    Gazaille C; Sicot M; Akiki M; Lautram N; Dupont A; Saulnier P; Eyer J; Bastiat G
    Pharm Res; 2021 Apr; 38(4):681-691. PubMed ID: 33829340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.